Never Run Out Of Buyers To Sell To.

Demeetra empowers biomanufacturers and researchers to move rapidly from precise gene edits to high-yield expression using a suite of proprietary, commercially accessible technologies. Our solutions optimize cell line development while eliminating common licensing and scalability barriers. Our Technologies: • Cas-CLOVER™: A high-fidelity nuclease that delivers clean, efficient gene knockouts and targeted knock-ins, with performance that rivals or exceeds CRISPR/Cas9. • Harbor-IN™: A license-free transposase that enables stable integration of large genetic payloads, achieving high titers…
Built from contact records that share this company: name, job title, job level, job function and person location.
Turn cold outreach into meaningful business conversations.
Rated and recommended by professionals who expect more
Annual Revenue$10M to $25M
Estimated OwnershipPrivateMatching runs on fields we already have: industry, employee range, HQ location, ownership type, funding rounds, specialities. Results come live from the ReachStream directory.